For example, an earlier study suggested that patients with mild to moderate Alzheimer’s disease and without ApoE4 allele might response to rosiglitazone treatment while those with such an allele would not response to the treatment [3]. The gene discussed is APOE; the disease is early-onset autosomal dominant Alzheimer disease.